RNS Number:4143Q Syntopix Group plc 31 January 2007 For immediate release 31 January 2007 SYNTOPIX GROUP PLC ('Syntopix' or 'the Group') AGREEMENT TO COMMENCE CLINICAL TRIALS Syntopix Group plc (AIM: SYN), the drug discovery and development group focused on dermatological diseases, is pleased to announce that it has signed an agreement with one of the world's largest clinical research organisations in preparation for the start of the Company's first Phase I clinical trial, which has the objective of developing a topical treatment for acne. The clinical trial, in a group of healthy volunteers, will be conducted on SYN0017, an anti-oxidant present in a number of food and cosmetic preparations, SYN0401, an anti-microbial ingredient in personal healthcare products, and a synergistic combination of SYN0017 and SYN0016, a well-known anti-acne ingredient. It will seek to confirm the antimicrobial activity and potential applications of these compounds and the combination treatment for acne patients. This Phase I study highlights the Company's strategy of seeking to reduce risk by concentrating on the change of use and novel combinations of known compounds with well documented pharmacology and toxicity profiles. The Phase I trial, which is expected to be completed within three months, will commence in the second quarter of 2007 subject to regulatory approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The Company's pipeline continues to evolve and additional clinical trials are planned for 2007 to evaluate further treatments for acne. Pre-clinical evaluation work will also be carried out in the second half of 2007 on SYN0017, both singly and as a synergistic combination in a prescription treatment for Staphylococcus aureus infections, including those due to MRSA. Steve Jones, Syntopix' CEO, commented: 'We are delighted to be at the point of making the transition from a research-based to a clinical-stage company, which marks a significant milestone for Syntopix. We have made rapid progress across our portfolio, endorsing the attractiveness of our business model in which novel uses are found for existing compounds.' ENDS For further information please contact: Syntopix Group plc 0845 125 9204 Stephen Jones, Chief Executive Officer Rod Adams, Chairman KBC Peel Hunt Ltd 020 7418 8900 Megan MacIntyre Buchanan Communications 020 7466 5000 Mark Court/Mary-Jane Johnson/Catherine Breen Notes to editors About Syntopix Group plc Syntopix, a group focused on the discovery and development of drugs for the topical treatment of dermatological diseases, was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading experts in skin microbiology, with initial funding from The Wellcome Trust. Syntopix' strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds; by concentrating on compounds and combinations of compounds that have a history of safe use; and working with compounds that have known properties, for example antimicrobials and anti-inflammatories. The Group currently has 10 pending UK patent applications. Syntopix is currently concentrating on acne and Staphylococcus aureus infections and has identified a pipeline of lead drug candidates that it intends to take through pre-clinical and, as appropriate, clinical trials. The Group intends to out-license products to commercial partners on obtaining proof of principle and to seek co-development partnerships. The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds. Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose Technology Limited and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For further information please visit www.syntopix.com. This information is provided by RNS The company news service from the London Stock Exchange END MSCSDUFASSWSEFF
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Synnovia PLC's (LON:SYN) chairman Faisal Rahmatallah tells Proactive London's Andrew Scott they saw record sales growth in the year to March 2019.
He adds that adjusted profits were just above flat as the plastic components and film packaging specialist invested for growth.